NVS Today - Aug 13: Small Dip After FDA News
Impossibile aggiungere al carrello
Puoi avere soltanto 50 titoli nel carrello per il checkout.
Riprova più tardi
Riprova più tardi
Rimozione dalla Lista desideri non riuscita.
Riprova più tardi
Non è stato possibile aggiungere il titolo alla Libreria
Per favore riprova
Non è stato possibile seguire il Podcast
Per favore riprova
Esecuzione del comando Non seguire più non riuscita
-
Letto da:
-
Di:
A proposito di questo titolo
So, what went down? Well, the stock kinda got smoked after some news hit about Pluvicto, which is one of their cancer treatments. The FDA gave a thumbs up for a combo approval, but it looks like traders weren’t too thrilled, and they hit that sell button fast. It’s like when your favorite band releases a new song, and it’s just not what you expected.
Now, let’s talk about why all this happened. First off, Novartis did win a court challenge in the UK related to its Entresto patent, which is a win for them, but the market seemed to shrug it off. Maybe folks were more focused on that Pluvicto news. Plus, I saw some reports saying that some big investors, like Triasima and Mission Wealth Management, are making moves with their shares—some buying more, others trimming down. It’s like a game of musical chairs where no one wants to be left standing when the music stops.
And speaking of the horizon, Novartis is working on optimizing its supply chain, which could be a big deal moving forward. If they nail that, it might help them streamline operations and improve profits.
So, yeah, today was a bit of a bummer for Novartis, but there’s always something brewing in the background. Just remember, I’m here to keep you in the loop, but this isn’t financial advice. Just some friendly chatter about the stock world. Catch you later!
adbl_web_anon_alc_button_suppression_t1
Ancora nessuna recensione